Thyroid dysfunction is usually investigated by measurement of a combination of serum thyroid hormones such as thyroxine (T4), tn-iodothyronine (T3) or their free hormones, and thyroid stimulating hormone (using a sensitive immunometric assay: sTSH). However, each of these measurements has its shortcomings and there are occasions when it is important to assess the tissue effects of thyroid h0rmones.l It has been shown that erythrocyte zinc (EZn) is subnormal in thyrotoxic~sis.~J However, changes in EZn lag behind those of thyroid hormones because of the relatively long half-life of erythrocyte~.~J Therefore, patients who are recovering from thyrotoxicosis may show relatively normal serum thyroid hormones and a subnormal EZn which will increase over the following weeks.
The usefulness of this characteristic was recently shown in the differential diagnosis of hyperthyroidism in pregnancy. EZn is reduced in patients with established thyrotoxicosis but normal in those suffering from transient hyperthyroidism of hyperemesis gra~idarum.4-~ In addition, it was shown recently6-' that EZn remains relatively undisturbed in subacute (painful) thyroiditis where the hyperthyroid phase develops acutely and usually lasts for 2 to 6 weeks.8 However, it might be expected that the EZn will be reduced in situations where the hyperthyroid phase is more prolonged. For instance, the hyperthyroid phase can last up to 12 months in subacute thyroiditk8
The diagnosis of transient thyrotoxicosis can be difficult especially when the patients are seen some weeks after the onset of symptoms. It is likely that some of these patients will have normal serum thyroid hormone levels by the time they are seen, a situation where conventional thyroid function tests are of limited value and the correct diagnosis may be missed. Therefore, a tissue marker like EZn which reflects the thyroid status over the preceding months may be useful. This is demonstrated in the following case.
CASE REPORT
A 45-year-old housewife, who had been treated elsewhere for Graves' disease 7 years previously, presented with a 10 month history of amenorrhea. In addition, she had tremor, palpitations and weight loss over the preceding 2 months. She had no neck pain. Her serum l T 4 and I T 3 measured 3 weeks previously were high. Her thyroid gland was slightly enlarged and clinically she appeared marginally thyrotoxic. Physicial examination was otherwise unremarkable. She was treated with propranolol. However, she did not take the propranolol because her symptoms improved spontaneously during the next 3 months and her weight increased.
Serial changes in body weight and thyroid hormone status are shown in Table 1 . The patient had elevated thyroid hormones which declined spontaneously associated with a suppressed sTSH which, subsequently, increased. EZn measured at 12 weeks after presentation, when the serum T, was normal, was reduced (99pmol/L of cells).
While the serum T4 remained within normal limits and the serum TSH returned to normal, the EZn increased spontaneously over the following weeks. These results suggested that the patient had an episode of transient thyrotoxicosis.
DISCUSSION
Subnormal EZn concentrations have only been reported in thyrotoxicosis and in sickle cell anaemia.9 Our patient did not have sickle cell anaemia. Patients who recover from thyrotoxicosis, typically show a rise in EZn.2-3 In thyrotoxic patients treated with anti-thyroid drugs, normalization of EZn on average lags behind the normalization of thyroid hormones by 3 months. Our patient had low EZn on presentation which progressively increased over the following months. Interpretation of serial changes in EZn requires knowledge of its critical difference.'O We have found that EZn has a critical difference of about 10% which implies that a serial result should be at least 10% different from the previous result to indicate that a significant change has occurred.
The changes in our patient were spontaneous and highly significant and strongly support the diagnosis of recovery from recent thyrotoxicosis.
We therefore conclude that EZn may be a useful addition to current thyroid function tests in the investigation of transient thyrotoxicosis, especially when there is delay in presentation. Serial changes in EZn may be the only clue to the diagnosis when serum thyroid hormone levels have returned to normal. EZn is unique in this respect because it is the only known retrospective marker of previous hyperthyroidism.
